<DOC>
	<DOC>NCT01459081</DOC>
	<brief_summary>The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.</brief_summary>
	<brief_title>Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Encephalitis, Herpes Simplex</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Who had fever (&gt;38.0ºC) At least two of the following symptoms: chills, headache, myalgia, fatigue, nasal symptoms, sore throat, cough Started therapy within 48 hours of onset of influenzalike illness Written informed consent Respiratory diseases, such as asthma or COPD Woman with a positive urine pregnancy test Woman without contraception during the study Allergic to zanamivir, Paracetamol or lactose WBC ≥ 10.5×109/L; neutrophil percentage ≥ 80% Hepatic function impairment: AST ≥ 2×ULN, ALT ≥ 2×ULN Renal function impairment: Cr &gt; 221μmol/L Influenza vaccination in the 12 months prior the beginning of the study History of tumor, psychiatric disorders, epilepsy or drug abuse Patients receiving corticosteroids, immunosuppressants HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>